Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes"

Transcription

1 Original Article Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes Simone Theilade, 1 Tine Willum Hansen, 1 Jens Peter Goetze, 2,3 and Peter Rossing 1,3,4 BACKGROUND To examine possible associations between midregional proatrial natriuretic peptide (MR-proANP) and diabetic complications at baseline and risk of mortality and end-stage renal disease (ESRD) during follow-up in type 1 diabetes. METHODS Observational study including 667 patients, with plasma MR-proANP measured at baseline. Complications were defined as micro- (n = 168) or macroalbuminuria (n = 190) (urinary albumin excretion rate (UAER) or 300 mg/24 h), previous cardiovascular disease (CVD) (n = 143), cardiac autonomic dysfunction (heart rate variability < 11 beats/min) (n = 369), and retinopathy (n = 523). Adjustments included gender, age, systolic blood pressure, estimated glomerular filtration rate (egfr), UAER, HbA 1c, total cholesterol, 24-hour urinary sodium excretion (24h-U Na ), body mass index, daily insulin dose, antihypertensive treatment, and smoking in linear regression analyses and analysis of covariance models. Development of ESRD (dialysis, renal transplantation, or GFR/eGFR < 15 ml/min/1.73 m 2 ) and mortality was recorded through national registers. RESULTS The cohort included 293 (44%) females, aged 55 ± 13 years. Plasma MR-proANP (median (interquartile)) was 74.7 ( ) pmol/l. Adjusted, MR-proANP correlated positively with age and UAER and negatively with egfr, 24h-U Na, total cholesterol, and HbA 1c (P < 0.05). Moreover, MR-proANP levels increased with albuminuria degree and were higher in patients with previous CVD (P 0.001), but similar in patients with or without autonomic dysfunction or retinopathy (P 0.076). During follow-up (3.5 ( ) years), higher MR-proANP concentrations predicted ESRD and mortality combined (n = 35) adjusted for gender, age, systolic blood pressure, egfr, and previous CVD (hazard ratio per 1SD increase in loganp: 2.8 ( ; P < 0.001)). CONCLUSIONS Increased plasma MR-proANP was associated with impaired renal function, increased albuminuria, and previous CVD. Moreover, MR-proANP concentrations were associated with increased risk of development of ESRD and mortality combined during follow-up. Keywords: atrial natriuretic peptide; blood pressure; diabetic complications; hypertension; natriuretic peptide, type 1 diabetes. doi: /ajh/hpu227 Atrial natriuretic peptide (ANP) is predominantly secreted from atrial myocytes in response to atrial stretch 1, regulates renal sodium and water secretion and reduces systemic blood pressure. 2,3 The hormone exerts its effects directly in the kidney and cardiovascular system as well as through inhibition of the renin-angiotensin-aldosterone system (RAAS) and sympathetic activity and by inducing endothelial modulation, 3 causing vasodilation, increased renal blood flow, and glomerular filtration (Figure 1). In hyperglycemia, RAAS activation induces raised blood pressure 4, which partly is counteracted by concurrent increased ANP secretion. 5 Interestingly, the overall opposing effect of ANP on blood pressure appears to be exaggerated in hypertension, 6 suggesting a general blood pressure regulatory effect. Despite the beneficial hormonal actions of ANP, higher concentrations in circulation may reflect hyposensitivity or increased release due to cardiac disease. This partly explains why higher concentrations are associated with worse outcome. In patients with type 1 diabetes, ANP concentrations are elevated, and incrementally so with presence of concurrent microalbuminuria, poor glycemic control, and hypertension. 7 In type 2 diabetes, higher ANP levels are associated with reduced kidney function and increased risk of cardiovascular events. 8 Furthermore, higher levels of ANP are associated with arterial stiffness 1,9 and severity of hypertension 1 and with increased mortality in unselected acutely hospitalized patients, 10 patients with heart failure, 11 ischemic heart disease, 12 and in dialysis patients. 13 Correspondence: Simone Theilade Initially submitted July 30, 2014; date of first revision August 25, 2014; accepted for publication October 20, 2014; online publication December 1, Steno Diabetes Center, Gentofte, Denmark; 2 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark; 3 Faculty of Health Sciences, Aarhus University, Aarhus, Denmark; 4 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. American Journal of Hypertension, Ltd All rights reserved. For Permissions, please American Journal of Hypertension 28(6) June 2015

2 MR-proANP in Type 1 Diabetes Figure 1. Atrial natriuretic peptide (ANP) regulation. Diagram of the ANP activation and action. Abbreviations: BP, blood pressure; ECV, extracellular volume; GFR, glomerular filtration rate; SNS, sympathetic nerve system. Due to the short half-life of ANP, the hormonal precursor, proanp, is often measured as a surrogate marker for cardiac ANP. 2 Brain natriuretic peptide (BNP), another more thoroughly investigated natriuretic peptide, has previously been found to predict heart failure and mortality in type 1 and 2 diabetes. 8,14,15 However, ANP regulates BP and reduces cardiac hypertrophy, while BNP regulates cardiac remodeling, 16 hence the 2 natriuretic hormones may not be interchangeable. In accordance with this, ANP appears to have a BNPindependent predictive value 17 and may be superior to BNP as a prognostic marker for mortality in patients with heart failure. 17,18 However, ANP is much less investigated in particular in patients with diabetes. In the current study in patients with type 1 diabetes, we measured midregional proanp and examined the crosssectional association with diabetes duration and diabetic complications. Moreover, we assessed the predictive value of MR-proANP measurement in relation to all-cause mortality and end-stage renal disease (ESRD) during follow-up. METHODS Study design and population The cohort has previously been described. 19 Briefly, during , Caucasian patients with type 1 diabetes but without ESRD (dialysis, renal transplantation, or glomerular filtration rate/estimated glomerular filtration rate (GFR/ egfr) < 15 ml/min/1.73 m 2 ) attending the outpatient clinic at the Steno Diabetes Center were recruited to enter a study examining diabetic complications. Of 1,285 patients invited, 676 (52.6 %) accepted to participate. The study conformed to the Declaration of Helsinki was approved by the local ethics committee, and all patients gave written informed consent. Clinical and laboratory methods Office blood pressure was measured after 15 minutes supine rest as the average of 3 left brachial measurements (UA787, A&D Medical, San Jose, CA). All patients had blood samples and phenotypic characteristics collected. HbA 1c was measured by high-performance liquid chromatography (normal range: 4.1% 6.4%, mmol/mol, Variant; Biorad Laboratories, Munich, Germany), plasma cholesterol and serum creatinine concentration by standardized methods. All participants had blood samples drawn and stored in EDTA plasma at 80 C for future analysis of biomarkers. After 1 thaw circle, MR-proANP was measured on the Kryptor platform (Thermo-Fisher, Germany) according to manufacturer s manual: The assay has been validated earlier in our laboratory (N-terminal proanp measurement in plasma suggests covalent modification). 20 Urinary albumin excretion rate (UAER) was measured in 2 sterile 24-hour urine collections obtained in connection with the study by enzyme immunoassay. Additional information on UAER was based on historical samples from medical records. Patients were stratified as normo-, micro-, or macroalbuminuric if UAER < 30 mg/24 h, mg/24 h, or 300 mg/24 h, respectively, in 2 out of 3 consecutive measurements within 6 months, in the absence of other kidney or urinary tract diseases. Patients with a history of persistently elevated UAER, subsequently reduced with treatment, were categorized according to historic elevated samples. Urinary sodium excretion was also determined as a geometric mean from the 24-hour urine samples. egfr was calculated by the 4 variables Modification of Diet in Renal Disease adapted to isotope dilution mass spectrophotometry-traceable creatinine measurements. Cardiovascular disease (CVD) was history of myocardial infarction, revascularization, peripheral arterial disease, or stroke. Cardiac autonomic function was assessed by heart rate variability recorded during paced deep breathing. A heart rate variability < 11 beats/min defined autonomic dysfunction. 21 Retinopathy status was obtained from medical records. All patients had regular ophthalmological exams, where retinopathy was assessed from retinal photographs taken through dilated pupils. Presence of retinopathy was either simple, proliferative or blindness based on the worst eye. Information on antihypertensive treatment was retrieved from patients medical records and cross-checked with the patients. Antihypertensive treatment included renin-angiotensin blocking agents, alpha, beta, and calcium blockers, spironolactone, moxonidine, and diuretics. Based on standardized questionnaires, current smoking was 1 cigarettes/cigars/pipes per day. Information on antihypertensive treatment was obtained from questionnaires and cross checked with medical records at Steno Diabetes Center. Ascertainment of events On 1 April 2014, we ascertained vital status and incidence of ESRD for all patients through the electronic patient s records at Steno Diabetes Center. These records are linked to a nationwide electronic registration of admissions and medical records from hospitalizations and are continuously updated from the Danish Civil Registration System with information on vital status. American Journal of Hypertension 28(6) June

3 Theilade et al. Statistical analysis Normally distributed variables are given as mean ± SD, whereas nonnormally distributed variables are given as median (interquartile range) and log transformed (base e) before analysis. Uni- and multivariate linear regression was used to compare levels of MR-proANP with covariates. Student s t-test, chi-square test, and analysis of variance were used for comparisons between groups, while analysis of covariance was applied for adjustment. Multiple logistic regression calculated odds ratios for diabetic complications per 1SD increase in loganp. All adjustments included gender, age, diabetes duration, systolic blood pressure, egfr, UAER, HbA 1c, total cholesterol, 24-hour urinary sodium excretion (24h-U Na ), body mass index, total daily insulin dose, antihypertensive treatment, and smoking. We modeled the risk of a combined end point of all-cause mortality or ESRD during follow-up in Cox regression analysis adjusted for gender, age, egfr, systolic blood pressure, and previous CVD (due to low number of events, no further adjustment was made). A 2-tailed P value < 0.05 was considered significant. Statistical analyses were performed using SPSS for Windows, version 20.0 (SPSS, Chicago, IL). RESULTS Characteristics Of the original cohort (n = 676), MR-proANP levels were available in 667 (98.7%) patients. In 9 patients, there was insufficient plasma for MR-proANP measurement. Table 1 shows characteristics of the analyzed cohort in total and divided into patients with normo-, micro-, and macroalbuminuria. Covariates Median (interquartile) MR-proANP was 74.7 ( ) pmol/l. MR-proANP correlated significantly with egfr (r = 0.59), age (r = 0.49), pulse pressure (r = 0.38), diabetes duration (r = 0.37), UAER (r = 0.34), systolic blood pressure (r = 0.25), 24h-U Na (r = 0.20), total daily insulin dose (r = 0.17), diastolic blood pressure (r = 0.14), HbA 1c (r = 0.11), total cholesterol (r = 0.10), and heart rate (r = 0.08) (P for all). MR-proANP levels were higher in smokers and in patients receiving antihypertensive treatment (P 0.028), but similar in men and women and did not correlate with body mass index (P 0.56). In multivariate analysis, MR-proANP levels correlated positive with age and UAER and negatively with egfr, 24h- U Na, total cholesterol, and HbA 1c (P 0.021). Diabetes duration Normoalbuminuric patients (n = 309) were split into patients with short (<10 years) (n = 94) and long diabetes duration (n = 215). MR-proANP levels were lower in patients with short vs. long diabetes duration (48.8 ( ) vs ( ) pmol/l; P < 0.001; Figure 2); however this attenuated after adjustment (P = 0.58; Figure 3). Moreover, adjusted analyses of diabetes duration as a continuous variable in both normoalbuminuric and all patients did not reveal any relationship between MR-proANP levels and diabetes duration (P 0.70). Complications MR-proANP increased with albuminuria degree, the levels for patients with normo-, micro-, and macroalbuminria were: 62.2 ( ), 75.8 ( ), and ( ) pmol/l (P < 0.001; Figure 2). This difference remained significant after adjustment (not including UAER in the model) (P = 0.001; Figure 3). Per 1SD increase in proanp, the odds ratio for albuminuria (micro- and macroalbuminuria combined) was 1.9 (P < 0.001; Table 2). Moreover, MR-proANP levels were higher in patients with (n = 143) vs. without previous CVD (116.5 ( ) vs ( ) pmol/l; P < 0.001, adjusted P < 0.001; Figures 2 and 3). Per 1SD increase in proanp, the odds ratio for previous CVD was 1.7 (P = 0.002; Table 2). Including pulse pressure and heart rate in the adjusted models did not alter the results (data not shown). Cardiac autonomic function was assessed in 623 patients. In patients with vs. without autonomic dysfunction (n = 369), MR-proANP levels were higher (90.7 ( ) vs ( ) pmol/l; P < 0.001; Figure 2). However, this difference disappeared after adjustment (P= 0.15). Retinopathy status was available in 664 patients. In patients with (n = 523) vs. without (n = 141) retinopathy, MR-proANP levels were higher (81.7 ( ) vs ( ) pmol/l; P < 0.001; Figure 2). But, adjustment attenuated the significance of this difference (P = 0.076). Follow-up During a median follow-up of 3.5 ( ) years, 22 (3.3%) patients died and 13 (1.9%) developed ESRD. None of the patients who developed ESRD died subsequently during the follow-up period. The MR-proANP concentrations in patients that experienced the combined event of death or ESRD were ( ) pmol/l compared with 72.3 ( ) pmol/l in patients without an event (P < 0.001; Figure 2). This difference remained significant following adjustment for gender, age, systolic blood pressure, and egfr (P < 0.001; Figure 3). Including pulse pressure and heart rate instead of or additional to systolic blood pressure did not alter the results (data not shown). In Cox regression, higher MR-proANP (per 1SD increase) predicted the combined event independent of gender, age, egfr, systolic blood pressure, and previous CVD (hazard ratio: 2.77 ( ; P < 0.001)). Including beta-blocker, calcium-blocker, and diuretic treatment in the model did not alter the results (hazard ratio: 2.80 ( )). Nor did exchanging systolic blood pressure with pulse pressure (hazard ratio: 2.70 ( )). 774 American Journal of Hypertension 28(6) June 2015

4 MR-proANP in Type 1 Diabetes Table 1. Baseline characteristics All patients (n = 667) Normoalbuminuria (n = 309) Microalbuminuria (n = 168) Macroalbuminuria (n = 190) P value Female (%) Age (years) 55 ± ± ± ± Diabetes duration (years) 33 ± ± ± ± 11 <0.001 egfr (ml/min/1.73 m 2 ) 83 ± ± ± ± 29 <0.001 UAER (mg/24 h) a 17 (8 65) 8 (6 12) 33 (17 61) 136 (33 479) HbA 1c (mmol/mol) 64 ± ± ± ± 14 <0.001 HbA 1c (%) 8.0 ± ± ± ± 1.2 <0.001 Total daily insulin dose (international units) 42 (32 59) 40 (30 55) 43 (33 62) 46 (34 60) Total cholesterol (mmol/l) 4.7 ± ± ± ± Urinary sodium excretion (mmol/24 h) 151 ( ) 151 ( ) 155 ( ) 148 ( ) 0.45 Body mass index (kg/m 2 ) 25.3 ± ± ± ± Antihypertensive medication, any (%) <0.001 Beta-blocker treatment (%) Calcium-blocker treatment (%) <0.001 Diuretic treatment (%) <0.001 Smokers (%) Systolic blood pressure (mm Hg) 132 ± ± ± ± Diastolic blood pressure (mm Hg) 74 ± 9 75 ± 9 73 ± 9 74 ± MR-proANP (pmol/l) 74.7 ( ) 62.2 ( ) 75.8 ( ) ( ) <0.001 Data represent percentage (%), mean ± SD, or median (interquartile range). P values are for unadjusted comparisons (ANOVA or chi-square test) between normo-, micro-, and macroalbuminuric patients. Abbreviations: ANOVA, analysis of variance; egfr, estimated glomerular filtration rate; MR-proANP, midregional proatrial natriuretic peptide; UAER, urinary albumin excretion rate. a Some patients with previously persistent macro- or macroalbuminuria had values <30 and <300 mg/24 h, respectively, at the time of investigation. American Journal of Hypertension 28(6) June

5 Theilade et al MR-proANP (pmol/ml) Figure 2. MR-proANP levels in patient groups. Bars showing median (interquartile range) levels of MR-proANP in different patient groups. P values are unadjusted ANOVA. : < Abbreviations: ANOVA, analysis of variance; ESRD, end-stage renal disease; MR-proANP, midregional proatrial natriuretic peptide. Figure 3. Adjusted MR-proANP (logarithmic) in patient groups. Bars showing adjusted marginal means and 95% confidence intervals in different patient groups. P values are adjusted ANCOVA. : <0.001, : <0.05. $: Adjusted for gender, age, diabetes duration, systolic blood pressure, egfr, UAER, HbA 1c, total cholesterol, 24-hour urinary sodium excretion (24h-U Na ), body mass index, total daily insulin dose, antihypertensive treatment, and smoking. #: Adjusted for gender, age, diabetes duration, systolic blood pressure, egfr, HbA 1c, total cholesterol, 24-hour urinary sodium excretion (24h-U Na ), body mass index, total daily insulin dose, antihypertensive treatment, and smoking. *: Adjusted for gender, age, egfr, systolic blood pressure, and previous CVD. Abbreviations: ANCOVA, analysis of covariance; CVD, cardiovascular disease; egfr, estimated glomerular filtration rate; ESRD, end-stage renal disease; MR-proANP, midregional proatrial natriuretic peptide; UAER, urinary albumin excretion rate. DISCUSSION In the current study, we examined the possible relationship between MR-proANP and diabetes duration and diabetic complications in patients with type 1 diabetes. Furthermore, we investigated the predictive value of MR-proANP measurement for the combined end point of ESRD and all-cause mortality during follow-up. We found that proanp concentrations were (i) independent of diabetes duration after adjustment, (ii) higher with increased degree of albuminuria and lower egfr, (iii) higher in patients with previous CVD, and (iv) associated with increased risk of all-cause mortality and ESRD combined. 776 American Journal of Hypertension 28(6) June 2015

6 MR-proANP in Type 1 Diabetes Table 2. Odds ratios for diabetic complications per 1SD increase in MR-proANP in 665 type 1 diabetic patients Odds ratio 95% Confidence interval P value Albuminuria (n = 358) a <0.001 Cardiovascular disease (n = 143) Autonomic dysfunction (n = 369) Retinopathy (n = 523) All adjustments included gender, age, diabetes duration, systolic blood pressure, egfr, urinary albumin excretion rate, HbA 1c, total cholesterol, 24-hour urinary sodium excretion, body mass index, total daily insulin dose, antihypertensive treatment, and smoking. Abbreviations: egfr, estimated glomerular filtration rate; MR-proANP, midregional proatrial natriuretic peptide a Albuminuria was micro- ( mg/24 h) and macroalbuminuria ( 300 mg/24 h) combined. Adjustments did not include urinary albumin excretion rate when examining the relationship between albuminuria and MR-proANP. Under physiological conditions, higher ANP concentrations in circulation reduce systemic blood pressure. Under pathological states in connection with CVD, however, high ANP concentrations are present 22 without the same effect on blood pressure control. The biological mechanisms are several, including altered ANP degradation, 23 concurrent increased intrarenal RAAS activation counteracting ANP activity, 24 increased sympathetic tone-blunting ANP response, 25 and reduced renal ANP receptors. 26 Finally, the paradoxical high concentrations of natriuretic peptides in the absence of peripheral effects may likely also be caused by impaired cardiac maturation of the natriuretic prohormones, as is seen in hyperinsulinemia with and increased proinsulin release. Higher proanp levels are associated with CVD events and impaired renal function in type 2 diabetes 8 and predict mortality in patients with CVD and ESRD We now demonstrate similar relationships in patients with type 1 diabetes. ANP blocks tubular protein reabsorption and increases glomerular filtration and permeability, 27,28 which may explain the association between albuminuria and proanp. 29 Hyperfiltration is an early occurrence in the development of diabetic nephropathy, 30 and as proanp stimulates GFR, it may be an early marker of diabetic kidney disease. Furthermore, in patients with microalbuminuria, ANP stimulation alters basal membrane properties leading to altered charge and size selectivity, ultimately increasing proteinuria and transcapillary escape of plasma proteins. 31 The concept of a cardiorenal syndrome, in which systemic, cardiac, or renal disease contributes to development of concurrent cardiac and renal disease, has previously been established. 32,33 Our data confirm this interaction between cardiac and renal disease. Moreover, as shown by others, 34 elevations of natriuretic peptides are not merely a result of impaired glomerular filtration as the relationship between MR-proANP and cardiorenal disease is independent of egfr. We did not measure BNP in the current cohort. BNP is already an established biomarker for impaired renal function, heart failure, and mortality (CVD and all-cause) in type 1 and 2 diabetes. 8,14,15 BNP is also secreted from the cardiac atria and reflects ventricular systolic function, while ANP is secreted also in response to diastolic dysfunction. 35 As diastolic dysfunction is frequent in asymptomatic type 1 diabetes, 36 progression of diastolic dysfunction to heart failure is potentially reversible with improved diabetes control. 37 Moreover, studies have shown that ANP may provide additional diagnostic value to BNP for heart failure 38 and may be superior to BNP in predicting mortality in heart failure patients. 17,18 Hence, ANP may be an early biomarker for screening patients at long-term risk of heart failure and thus suitable for intensified diabetes management. As ANP counteracts RAAS, endothelin synthesis, and sympathetic activity, 39 the hormone constitutes a potential therapeutic target in management of hypertension and CVD. Currently, only 1 single ANP analogue is commercially available. Carperitide has shown promising cardiorenal effects in patients with acute heart failure and patients undergoing coronary bypass surgery. 40,41 Neutral endopeptidases are enzymes that breakdown ANP. Recently, the PARADIGM HF trial, examining the effect of enalapril vs. a neutral endopeptidase inhibitor in combination with valsartan on outcome in patients with heart failure, was stopped prematurely due to overwhelming improved outcome in the combination treatment arm. However, although ANP therapy may potentially improve blood pressure control and cardiorenal function, the side effects of neutral endopeptidase inhibition therapy may be significant, 42 and data on drug interference with the ANP activity are still limited. However, although not a major pharmacologic target at present, ANP remains a strong biomarker for cardiorenal failure. 43,44 Our data expand the present knowledge by documenting that higher MR-proANP concentrations are related to impaired renal function and presence of CVD in patients with type 1 diabetes. Interestingly, diabetes duration did not appear to affect proanp concentrations and was unrelated to autonomic dysfunction and retinopathy. Regardless, proanp may prove to be a useful biomarker for monitoring outcome of diabetes. Furthermore, continued attempts at developing novel pharmacologic agents targeting ANP-RAAS homeostasis may improve the management of diabetes altogether. Strengths and limitations We used the propeptide (proanp) as a surrogate for ANP, as it has a longer half-life and is stable in vitro. However, levels of proanp generally correspond well to levels of the active hormone. 2 MR-proANP levels were measured from stored samples after 3.5 years, following only 1 thawing cycle. But, levels of appear to be stable after freeze-thaw cycles. 45 Patients were not fasting prior to blood sampling, although food American Journal of Hypertension 28(6) June

7 Theilade et al. intake has been shown to affect MR-proANP levels in healthy individuals. 46 However, given the patients type 1 diabetes status, this would not have been a safe option for all. Blood tests were not drawn at a specific time in all patients. However, plasma ANP does not show significant diurnal variation. 47 We did not measure N-terminal-proBNP, as the primary aim was to assess the relationship of MR-proANP and diabetic complications, hence we cannot compare the 2 markers in this study. Previous CVD was based on patient recollection and medical records. Thus, we may have underestimated the prevalence of CVD (silent ischemia). Furthermore, we dichotomized presence of retinopathy and autonomic dysfunction and only used 1 test to define autonomic function. Thus, all 3 measures of complications are crude, and weakened the retinopathy and autonomic function variables. However, the majority of patients had been followed at the Steno Diabetes Center for more than a decade, rendering the information on diabetic complications very reliable. Moreover, follow-up data were acquired from the Steno Diabetes Center electronic patient record, which is linked to nationwide electronic databases, consequently no patients were lost to follow-up. Number of follow-up events were few, hence we created the combined end point of all-cause mortality and ESRD, which we have used in a previous publication, 48,49 and yet we were still only able to include a limited number of variables in the adjusted model. Moreover, we did not asses the development of heart failure. Importantly, the current cohort only included Caucasian patients, and as MR-proANP levels differ significantly between races, 50 our results may not be suited for extrapolation to non-caucasian races. Major strengths are the large cohort and single-center setup. CONCLUSIONS In the current cohort, increased MR-proANP concentrations were associated with impaired renal function, increased albuminuria degree, and presence of CVD. Moreover, higher MR-proANP was associated with increased risk of all-cause mortality and ESRD combined during follow-up. Although, being a potential agent against cardiovascular and renal disease, ANP may also be a risk marker for CVD and other complications in patients with type 1 diabetes, when levels are elevated beyond physiological control. DISCLOSURE The authors declared no conflict of interest. REFERENCES 1. Khaleghi M, Saleem U, Morgenthaler NG, Turner ST, Bergmann A, Struck J, Mosley TH, Kullo IJ. Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. Am J Hypertens 2009; 22: Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991; 60: Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999; 10: Jacobsen P, Rossing K, Hansen BV, Bie P, Vaag A, Parving HH. Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients. J Intern Med 2003; 254: Eiskjaer H, Nielsen CB, Pedersen EB. Pressure-dependent, enhanced natriuretic response to low-dose, atrial natriuretic peptide infusion in essential hypertension. J Intern Med 1994; 236: McKenna K, Smith D, Sherlock M, Moore K, O Brien E, Tormey W, Thompson CJ. Elevated plasma concentrations of atrial and brain natriuretic peptide in type 1 diabetic subjects. Ir J Med Sci 2005; 174: Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R, Hülsmann M. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009; 32: Coutinho T, Turner ST, Mosley TH, Kullo IJ. Biomarkers associated with pulse pressure in African-Americans and non-hispanic whites. Am J Hypertens 2012; 25: Lauridsen BK, Iversen K, Hunter I, Bay M, Kirk V, Nielsen OW, Nielsen H, Boesgaard S, Køber L, Goetze JP. ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. BMJ Open 2013; 3:e Bosselmann H, Egstrup M, Rossing K, Gustafsson I, Gustafsson F, Tonder N, Kistorp CN, Goetze JP, Schou M. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol 2013; 170: Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012; 125: Gouya G, Sturm G, Lamina C, Zitt E, Freistätter O, Struck J, Wolzt M, Knoll F, Lins F, Lhotta K, Neyer U, Kronenberg F. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 2011; 6:e Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48: Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-b-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; 191: von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-b-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009; 53: Theilade S, Lajer M, Persson F, Joergensen C, Rossing P. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 2013; 36: Hunter I, Alehagen U, Dahlström U, Rehfeld JF, Crimmins DL, Goetze JP. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clin Chem 2011; 57: American Journal of Hypertension 28(6) June 2015

8 MR-proANP in Type 1 Diabetes 21. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285: Shenker Y, Sider RS, Ostafin EA, Grekin RJ. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 1985; 76: Clerico A, Iervasi G. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? J Card Fail 1995; 1: Showalter CJ, Zimmerman RS, Schwab TR, Edwards BS, Opgenorth TJ, Burnett JC Jr. Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II. Am J Physiol 1988; 254:R453 R Feng QP, Hedner T, Hedner J, Pettersson A. Blunted renal response to atrial natriuretic peptide in congestive heart failure rats is reversed by the alpha 2-adrenergic agonist clonidine. J Cardiovasc Pharmacol 1990; 16: Sechi LA, Valentin JP, Griffin CA, Lee E, Bartoli E, Humphreys MH, Schambelan M. Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus. J Clin Invest 1995; 95: Naomi S, Umeda T, Iwaoka T, Miura F, Kitamoto Y, Nakayama M, Sato T. A possible contribution of endogenous atrial natriuretic peptide to proteinuria in patients with chronic renal failure. Endocrinol Jpn 1991; 38: Vervoort G, Wetzels JF, Lutterman JA, Bravenboer B, Berden JH, Smits P. Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. Am J Kidney Dis 2002; 40: Jacobs EM, Vervoort G, Branten AJ, Klasen I, Smits P, Wetzels JF. Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29: Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986; 46: Parving HH, Kastrup J, Smidt UM. Reduced transcapillary escape of albumin during acute blood pressure-lowering in type 1 (insulindependent) diabetic patients with nephropathy. Diabetologia 1985; 28: Hashimoto J, Ito S. Central pulse pressure links microalbuminuria with plasma B-type natriuretic peptide elevation: causal implication for cardiorenal syndrome in hypertension. J Hypertens 2014; 32: Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT; PREVEND Study Group. Highsensitive troponin T and N-terminal pro-b type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 2012; 33: Bayerle-Eder M, Zangeneh M, Kreiner G, Raffesberg W, Nowotny P, Vierhapper H, Waldhäusl W, Wolzt M, Pleiner H, Gasic S. ANP but not BNP reflects early left diastolic dysfunction in type 1 diabetics with myocardial dysinnervation. Horm Metab Res 2003; 35: Jensen MT, Sogaard P, Andersen HU, Bech J, Hansen TF, Galatius S, Jørgensen PG, Biering-Sørensen T, Møgelvang R, Rossing P, Jensen JS. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia 2014; 57: Dinh W, Lankisch M, Nickl W, Scheyer D, Scheffold T, Kramer F, Krahn T, Klein RM, Barroso MC, Füth R. Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc Diabetol 2010; 9: Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009; 13:R Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: Hattori H, Minami Y, Mizuno M, Yumino D, Hoshi H, Arashi H, Nuki T, Sashida Y, Higashitani M, Serizawa N, Yamada N, Yamaguchi J, Mori F, Shiga T, Hagiwara N. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels 2013; 28: Sezai A, Nakata K, Iida M, Yoshitake I, Wakui S, Hata H, Shiono M. Results of low-dose carperitide infusion in high-risk patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2013; 96: Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41: Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-a-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007; 13: Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009; 75: Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: Goetze JP. Plasma proanp decreases after meal intake. Clin Chem 2013; 59: Chiang FT, Tseng CD, Hsu KL, Lo HM, Tseng YZ, Hsieh PS, Wu TL. Circadian variations of atrial natriuretic peptide in normal people and its relationship to arterial blood pressure, plasma renin activity and aldosterone level. Int J Cardiol 1994; 46: Theilade S, Hansen TW, Rossing P. Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes. Am J Hypertens 2014; 27: Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005; 68: Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Anand IS, Wu AH, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Filippatos GS, Di Somma S, Ng L, Neath SX, Christenson R, Morgenthaler NG, Anker SD, Maisel AS. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012; 14: American Journal of Hypertension 28(6) June

Microvascular Disease in Type 1 Diabetes

Microvascular Disease in Type 1 Diabetes Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course

More information

Plasma N-terminal pro-b-type natriuretic peptide and mortality in type 2 diabetes

Plasma N-terminal pro-b-type natriuretic peptide and mortality in type 2 diabetes Diabetologia (2006) 49:2256 2262 DOI 10.1007/s00125-006-0359-4 ARTICLE Plasma N-terminal pro-b-type natriuretic peptide and mortality in type 2 diabetes L. Tarnow & M.-A. Gall & B. V. Hansen & P. Hovind

More information

E.Ritz Heidelberg (Germany)

E.Ritz Heidelberg (Germany) Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

Diabetic Nephropathy. Anna Vinnikova, M.D. Associate Professor Division of Nephrology

Diabetic Nephropathy. Anna Vinnikova, M.D. Associate Professor Division of Nephrology Diabetic Nephropathy Anna Vinnikova, M.D. Associate Professor Division of Nephrology Syndrome of inappropriate hyperglycemia due to either insulin deficiency or insulin resistance Type 1: is absolute deficiency

More information

Kidney Disease, Hypertension and Cardiovascular Risk

Kidney Disease, Hypertension and Cardiovascular Risk 1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,

More information

Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction

Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction Clin Kidney J (2013) 6: 55 62 doi: 10.1093/ckj/sfs174 Advance Access publication 21 December 2012 Original Article Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal

More information

Albuminuria: A target for treatment? Todd W.B. Gehr, M.D. Professor of Medicine

Albuminuria: A target for treatment? Todd W.B. Gehr, M.D. Professor of Medicine Albuminuria: A target for treatment? Todd W.B. Gehr, M.D. Professor of Medicine Virginia Commonwealth University ESRD Incidence Rates* by 150 Primary Diagnosis, 1988 1997 Rate/Million Pop./Year 100 Diabetes

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study

Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study Diabetologia (2014) 57:672 680 DOI 10.1007/s00125-014-3164-5 ARTICLE Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study

More information

Serum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy

Serum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy The Journal of International Medical Research 2010; 38: 95 99 Serum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy Z-Z LI 1, X-Z LU 2, J-B LIU 1 AND L CHEN 1 1 Department of Endocrinology,

More information

Diabetologia 9 Springer-Verlag 1981

Diabetologia 9 Springer-Verlag 1981 Diabetologia (1981) 20:457-461 Diabetologia 9 Springer-Verlag 1981 A Prospective Study of Glomerular Filtration Rate and Arterial Blood Pressure in Insulin-Dependent Diabetics with Diabetic Nephropathy

More information

23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen

23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Preventing the cardiovascular complications of hypertension

Preventing the cardiovascular complications of hypertension European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

Blood Pressure Regulation. Faisal I. Mohammed, MD,PhD

Blood Pressure Regulation. Faisal I. Mohammed, MD,PhD Blood Pressure Regulation Faisal I. Mohammed, MD,PhD 1 Objectives Outline the short term and long term regulators of BP Know how baroreceptors and chemoreceptors work Know function of the atrial reflex.

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

The Cardiorenal Syndrome in Heart Failure

The Cardiorenal Syndrome in Heart Failure The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic

More information

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression

More information

Diabetic Nephropathy

Diabetic Nephropathy Diabetic Nephropathy Outline Introduction of diabetic nephropathy Manifestations of diabetic nephropathy Staging of diabetic nephropathy Microalbuminuria Diagnosis of diabetic nephropathy Treatment of

More information

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography

Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography Yohei Oda 1, Muhei Tanaka 2, Michiaki Fukui 2, Sei Tsunoda 1, Satoshi Akabame

More information

RENIN ANGIOTENSIN SYSTEM MODULATION IN CARDIOVASCULAR DISEASE DR. CHARLES KARIUKI INTERVENTIONAL CARDIOLOGIST

RENIN ANGIOTENSIN SYSTEM MODULATION IN CARDIOVASCULAR DISEASE DR. CHARLES KARIUKI INTERVENTIONAL CARDIOLOGIST RENIN ANGIOTENSIN SYSTEM MODULATION IN CARDIOVASCULAR DISEASE DR. CHARLES KARIUKI INTERVENTIONAL CARDIOLOGIST THE CARDIOVASCULAR CONTINUUM Concept proposed in 1991 by Victor Dzau and Eugene Branwald Proposed

More information

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Objectives. Kidney Complications With Diabetes. Case 10/21/2015 Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review

More information

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension (2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with

More information

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT

More information

Relation between the angiotensinogen (AGT) M235T gene polymorphism and blood pressure in a large, homogeneous study population

Relation between the angiotensinogen (AGT) M235T gene polymorphism and blood pressure in a large, homogeneous study population (2003) 17, 555 559 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Relation between the angiotensinogen (AGT) M235T gene polymorphism and blood

More information

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the

More information

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the

More information

Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης

Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης Ιατρική Σχολή ΑΠΘ Νοσοκομείο ΑΧΕΠA Θεσσαλομίκη Kidney in body homeostasis Excretory function Uremic toxins removal Vascular volume maintainance Fluid-electrolyte

More information

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this

More information

University of Groningen. C-reactive protein and albuminuria Stuveling, Erik Marcel

University of Groningen. C-reactive protein and albuminuria Stuveling, Erik Marcel University of Groningen C-reactive protein and albuminuria Stuveling, Erik Marcel IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management

Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management (2000) 14, 667 685 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Responding to the challenge of diabetic nephropathy: the historic evolution of

More information

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

Title:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke

Title:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke Author's response to reviews Title:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke Authors: Kashif W Faiz (kashif.faiz@medisin.uio.no) Bente Thommessen (bente.thommessen@ahus.no)

More information

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA

More information

Therapeutic approaches to slowing the progression of diabetic nephropathy is less best?

Therapeutic approaches to slowing the progression of diabetic nephropathy is less best? www.drugsincontext.com The journal of interventions in clinical practice REVIEW Therapeutic approaches to slowing the progression of diabetic nephropathy is less best? FULL TEXT ARTICLE Eva Vivian, 1 Chelsea

More information

Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice

Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice (2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and

More information

Renal Quiz - June 22, 21001

Renal Quiz - June 22, 21001 Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular

More information

6/6/17. Heart Failure and Natriuretic Peptides. Learning objectives

6/6/17. Heart Failure and Natriuretic Peptides. Learning objectives Heart Failure and Natriuretic Peptides Maria-Magdalena Patru, MD, PhD Director, Medical and Scientific Affairs This promotional educational activity is brought to you by Ortho-Clinical Diagnostics, Inc.

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Blood Pressure. a change in any of these could cause a corresponding change in blood pressure

Blood Pressure. a change in any of these could cause a corresponding change in blood pressure Blood Pressure measured as mmhg Main factors affecting blood pressure: 1. cardiac output 2. peripheral resistance 3. blood volume a change in any of these could cause a corresponding change in blood pressure

More information

Prevalence and risk factor analysis of microalbuminuria in Japanese general population: The Takahata study

Prevalence and risk factor analysis of microalbuminuria in Japanese general population: The Takahata study http://www.kidney-international.org & 2006 International Society of Nephrology original article Prevalence and risk factor analysis of microalbuminuria in Japanese general population: The Takahata study

More information

Morning Hypertension: A Pitfall of Current Hypertensive Management

Morning Hypertension: A Pitfall of Current Hypertensive Management Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between

More information

ANTI- HYPERTENSIVE AGENTS

ANTI- HYPERTENSIVE AGENTS CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is

More information

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,

More information

Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance

Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Overview Introduction Mechanisms

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

DIABETES AND CHRONIC KIDNEY DISEASE

DIABETES AND CHRONIC KIDNEY DISEASE DIABETES AND CHRONIC KIDNEY DISEASE Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes

More information

ENDPOINTS FOR AKI STUDIES

ENDPOINTS FOR AKI STUDIES ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS

More information

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Stopping the Revolving Door of ADHF

Stopping the Revolving Door of ADHF Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information

Diabetic Nephropathy in Spontaneously Diabetic Torii (SDT) Rats

Diabetic Nephropathy in Spontaneously Diabetic Torii (SDT) Rats The Open Diabetes Journal, 2011, 4, 45-49 45 Diabetic Nephropathy in Spontaneously Diabetic Torii (SDT) Rats Takeshi Ohta * and Tomohiko Sasase Open Access Biological/Pharmacological Research Laboratories,

More information

N-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease

N-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease The new england journal of medicine original article N-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease Charlotte Kragelund, M.D., Bjørn Grønning, M.D.,

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Heart Failure and Renal Disease Cardiorenal Syndrome

Heart Failure and Renal Disease Cardiorenal Syndrome Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National

More information

New Concepts in Diabetes Underwriting 2017

New Concepts in Diabetes Underwriting 2017 New Concepts in Diabetes Underwriting 2017 William Figura Director of Underwriting Metropolitan Underwriting Discussion Group Annual Meeting January 2017 Michael Clark, MD Chief Medical Director Penn Mutual

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Faculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease

Faculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease Faculty The Role of the Kidney in Cardiometabolic Disease Christian W. Mende, MD, FACP, FACN, FASN, FASH Clinical Professor of Medicine University of California at San Diego San Diego, California Disclosures

More information

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years

More information

Springer-Verlag 1981

Springer-Verlag 1981 Diabetologia (1981) 21:178-183 Diabetologia @ Springer-Verlag 1981 Diabetic Nephropathy: Fault or Destiny? T. Deckert and J. E. Poulsen Steno Memorial Hospital, Gentofte, Denmark Summary. Twenty-one young

More information

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study http://www.kidney-international.org & 28 International Society of Nephrology original article Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study GL Bakris 1, RD

More information

CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE

CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease Greg Wellenius Joel Kaufman Framework for Choosing Subclinical Outcomes To Study What clinical outcomes

More information

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Cardiorenal End Points in a Trial of for Type 2 Diabetes Hans-Henrik Parving, M.D., D.M.Sc., Barry M. Brenner, M.D., Ph.D., John J.V.

More information

Effects of statins on renal sodium and water handling

Effects of statins on renal sodium and water handling Nephrol Dial Transplant (2008) 23: 1556 1561 doi: 10.1093/ndt/gfm807 Advanced Access publication 8 December 2007 Original Article Effects of statins on renal sodium and water handling Acute and short-term

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2016 January 01.

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2016 January 01. The Balance of the Evidence on Acid-Base Homeostasis and Progression of CKD Julia J. Scialla, MD, MHS 1,2 1 Division of Nephrology, Duke University School of Medicine, Durham, NC 2 Duke Clinical Research

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension

More information

Prevalence of left ventricular hypertrophy in a hypertensive population

Prevalence of left ventricular hypertrophy in a hypertensive population European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.

More information

Hyponatremia in Heart Failure: why it is important and what should we do about it?

Hyponatremia in Heart Failure: why it is important and what should we do about it? Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and

More information

Zuni Health Initiative

Zuni Health Initiative ZUNI JEWELRY Zuni Health Initiative Raj Shah-University of New Mexico vshah@salud.unm.edu Do' tse'mak i:k'oshudu, elek'yanna!!! May you feel better, everything will be alright!!! OBJECTIVES Describe the

More information

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2 Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic

More information

Krediet slide di 18

Krediet slide di 18 1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision

More information

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei

More information

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished

More information

Renal protection by inhibition of the renin-angiotensinaldosterone

Renal protection by inhibition of the renin-angiotensinaldosterone Renal protection by inhibition of the renin-angiotensinaldosterone system Tomas Berl Key words: angiotensinconverting enzyme inhibitor, angiotensin receptor blocker, combination therapy, direct renin inhibitor,

More information

Challenges to Manage Blood Pressure in ESRD and Heart Failure Patients

Challenges to Manage Blood Pressure in ESRD and Heart Failure Patients Challenges to Manage Blood Pressure in ESRD and Heart Failure Patients Shweta Bansal, MD, FASN Associate Professor of Medicine UT Health San Antonio 2nd Annual Cardiorenal Connections Meeting, April 28,

More information

Diabetic nephropathy affects 25 30% of type 1

Diabetic nephropathy affects 25 30% of type 1 Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients An Indicator of More Advanced Glomerular Lesions M. Luiza Caramori, 1 Paola Fioretto, 2 and Michael Mauer 1 Increased urinary

More information

CANVAS Program Independent commentary

CANVAS Program Independent commentary CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received

More information

Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion.

Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion. The Kidney Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion. The kidney has 6 roles in the maintenance of homeostasis. 6 Main Functions 1. Ion Balance

More information

The prevalence of albuminuria among diabetic patients in a primary care setting in Singapore

The prevalence of albuminuria among diabetic patients in a primary care setting in Singapore Singapore Med J 2015; 56(12): 681-686 doi: 10.11622/smedj.2015189 The prevalence of albuminuria among diabetic patients in a primary care setting in Singapore Eng Sing Lee 1, MBChB, MMed, Wern Ee Tang

More information